Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

SPA for phase III GVAX prostate cancer vaccine trial

May 12, 2004

Novel human anticancer vaccine elicits cellular responses

May 12, 2004

Australian Pentrys phase II trial commences

May 5, 2004

Phase II TroVax trial cleared to commence for metastatic renal cancer

May 3, 2004

Positive data for HuMax-CD4 in phase II CTCL studies

April 30, 2004

Esteve takes marketing rights to Wilex's Rencarex in Southern Europe

April 30, 2004

Phase III results of R-1549 in ovarian cancer disappoint

April 28, 2004

Aastrom receives grant to develop immunotherapy for malignant melanoma

April 27, 2004

Phase II trial studies Xcellerated T Cells for multiple myeloma

April 20, 2004

Scottish government grant supports anti-CD55 antibody development at Viragen

April 20, 2004

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...